Published in Proc Natl Acad Sci U S A on February 09, 2005
Spheroid-based drug screen: considerations and practical approach. Nat Protoc (2009) 4.01
Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A (2009) 2.12
Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep (2012) 1.81
Taxane benefit in breast cancer--a role for grade and chromosomal stability. Nat Rev Clin Oncol (2013) 0.89
Multi-layered cancer chromosomal instability phenotype. Front Oncol (2013) 0.88
Targeting karyotypic complexity and chromosomal instability of cancer cells. Curr Drug Targets (2010) 0.84
An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency. PLoS One (2013) 0.80
Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues. Chromosome Res (2016) 0.79
Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis. PLoS One (2012) 0.77
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Effects of cytochalasin and phalloidin on actin. J Cell Biol (1987) 10.32
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
The chromosomal basis of human neoplasia. Science (1983) 4.26
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res (1992) 2.62
Vascular targeting agents as cancer therapeutics. Clin Cancer Res (2004) 2.43
Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer (1999) 2.19
Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res (1988) 1.95
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des (1997) 1.89
Shaping of tumor and drug-resistant genomes by instability and selection. Oncogene (2003) 1.70
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol (2002) 1.68
Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells. J Natl Cancer Inst (2000) 1.64
Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev (2003) 1.47
Clinical significance of cytogenetic findings in solid tumors. Cancer Genet Cytogenet (1997) 1.46
Structure of cytochalasins and cytochalasin B binding sites in human erythrocyte membranes. Biochemistry (1980) 1.41
A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition. Proc Natl Acad Sci U S A (2003) 1.30
Perspectives on the development of a molecularly targeted agent. Cancer Cell (2002) 1.21
Multimodal action of antitumor agents on DNA: the ellipticine series. Arch Biochem Biophys (1987) 1.14
Rescue of mutant p53 transcription function by ellipticine. Oncogene (2003) 1.14
Intercalative binding of ellipticine to DNA. Cancer Res (1975) 1.09
Cytogenetic aberrations in colorectal adenocarcinomas and their correlation with clinicopathologic features. Cancer (1993) 1.05
Correlation between karyotypic pattern and clincopathologic features in 125 breast cancer cases. Int J Cancer (1996) 1.04
Combretastatins: from natural products to drug discovery. Nat Prod Rep (2003) 1.03
Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol (1998) 1.01
Tumor karyotype predicts clinical outcome in colorectal cancer patients. J Clin Oncol (2004) 0.96
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res (2002) 0.82
Gateways to clinical trials. Methods Find Exp Clin Pharmacol (2003) 0.80
Karyotypic pattern of pancreatic adenocarcinomas correlates with survival and tumour grade. Int J Cancer (1994) 0.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics (2005) 14.02
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol (2003) 8.66
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Nova regulates brain-specific splicing to shape the synapse. Nat Genet (2005) 6.58
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol (2007) 3.51
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics (2007) 2.93
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet (2003) 2.30
Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev (2003) 2.22
A stromal gene signature associated with inflammatory breast cancer. Int J Cancer (2008) 2.18
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res (2008) 2.01
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics (2012) 1.71
The interactive online SKY/M-FISH & CGH database and the Entrez cancer chromosomes search database: linkage of chromosomal aberrations with the genome sequence. Genes Chromosomes Cancer (2005) 1.70
Drug discovery: Cell lines battle cancer. Nature (2012) 1.70
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol (2013) 1.68
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
TCPA: a resource for cancer functional proteomics data. Nat Methods (2013) 1.64
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem (2008) 1.61
Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res (2007) 1.60
Finding fusion genes resulting from chromosome rearrangement by analyzing the expressed sequence databases. Proc Natl Acad Sci U S A (2004) 1.59
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
Quality assessment of microarrays: visualization of spatial artifacts and quantitation of regional biases. BMC Bioinformatics (2005) 1.52
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res (2007) 1.51
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 1.51
Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas. Cancer Genet Cytogenet (2004) 1.49
VennMaster: area-proportional Euler diagrams for functional GO analysis of microarrays. BMC Bioinformatics (2008) 1.49
DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators. Proc Natl Acad Sci U S A (2006) 1.48
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A (2006) 1.46
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res (2005) 1.42
Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther (2007) 1.42
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
The EDGE hypothesis: epigenetically directed genetic errors in repeat-containing proteins (RCPs) involved in evolution, neuroendocrine signaling, and cancer. Front Neuroendocrinol (2008) 1.37
SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics (2012) 1.36
Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res (2002) 1.34
PurityEst: estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics (2012) 1.33
Sequencing and analysis of 10,967 full-length cDNA clones from Xenopus laevis and Xenopus tropicalis reveals post-tetraploidization transcriptome remodeling. Genome Res (2006) 1.31
BreakFusion: targeted assembly-based identification of gene fusions in whole transcriptome paired-end sequencing data. Bioinformatics (2012) 1.31
A rhodium(III) complex for high-affinity DNA base-pair mismatch recognition. Proc Natl Acad Sci U S A (2003) 1.30
SpliceCenter: a suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies. BMC Bioinformatics (2008) 1.29
Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res (2006) 1.28
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther (2008) 1.28
Molecular interaction maps--a diagrammatic graphical language for bioregulatory networks. Sci STKE (2004) 1.27
Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. Mol Biol Cell (2004) 1.27
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res (2006) 1.26
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother (2005) 1.25
Exposing the cancer genome atlas as a SPARQL endpoint. J Biomed Inform (2010) 1.25
SpliceMiner: a high-throughput database implementation of the NCBI Evidence Viewer for microarray splice variant analysis. BMC Bioinformatics (2007) 1.25
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron. Cancer Res (2010) 1.24
Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res (2005) 1.22